-
Anti-RPS6 Antibody: MA4974 Research Guide
2026-08-11
The Anti-RPS6 antibody MA4974 is an affinity-purified mouse monoclonal reagent for detecting human, mouse, rat, and monkey RPS6 in Western blot, ICC/IF, and immunoprecipitation workflows. It provides a defined research tool for connecting RPS6 measurements with ribosome biogenesis, cell signaling, and cancer-biology studies, while remaining unsuitable for diagnostic or medical use.
-
MAPK10–KRT16 Signaling in NSCLC Metastasis
2026-08-10
The reference study identifies a phosphorylation-dependent MAPK10–KRT16–RNF213 pathway that suppresses non-small cell lung cancer metastasis by promoting KRT16 ubiquitination and proteasomal degradation. Its combination of mechanistic, cellular, animal, and clinical evidence positions this axis as a potential biomarker framework while also highlighting the need for more specific pathway validation.
-
SARS-CoV-2 Nucleocapsid Condensation and GCG
2026-08-09
The reference study identifies RNA-triggered liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic step in viral biology. It further shows that the green-tea polyphenol (-)-gallocatechin gallate disrupts nucleocapsid condensation and suppresses viral replication, establishing condensate regulation as a potential antiviral research direction.
-
tFUS–Nespas–SHP2 Axis in Ischemic Stroke
2026-08-08
A 2025 study links low-intensity transcranial focused ultrasound stimulation (tFUS) with suppression of post-stroke NLRP3 neuroinflammation through the Nespas/miR-383-3p/SHP2 pathway. Using rat ischemic stroke and BV2 microglial models, the work combines behavioral, molecular, transcriptomic, and gene-perturbation evidence to define a mechanistic route for tFUS-mediated neuroprotection.
-
LRPPRC–Dasatinib Synergy in OXPHOS-Dependent Tumors
2026-08-07
The reference study identifies Dasatinib as a synergistic partner for LRPPRC inhibition, using a screen of 1,376 FDA-approved compounds and validation in cancer models. Its central mechanistic insight is that the combination blocks OXPHOS at two levels: LRPPRC inhibition preferentially disrupts mitochondrial genome-encoded components, whereas Dasatinib suppresses nuclear-encoded OXPHOS genes.
-
MRT68921 ULK1 Kinase Inhibitor: Advancing Autophagy Research
2026-08-07
MRT68921 empowers researchers to dissect autophagy signaling with nanomolar precision, offering robust inhibition of ULK1/2 for detailed mechanistic studies. Its selectivity and validated workflows make it indispensable for advanced autophagy inhibition and lipid metabolism research.
-
RIPA Lysis Buffer Strong: Precision Tools for Translational
2026-08-06
Explore how APExBIO’s RIPA Lysis Buffer (Strong, without inhibitors) empowers translational researchers to achieve high-fidelity protein extraction for advanced immunological and biochemical assays. This thought-leadership article integrates mechanistic insights, protocol guidance, and strategic perspectives, bridging preclinical discovery with clinical translation in cancer and immunology.
-
Arachidonic Acid: Molecular Nexus in Immunity and Signal Tra
2026-08-06
Discover how arachidonic acid, a polyunsaturated omega-6 fatty acid, shapes immune responses and cellular signaling. This article provides a deep scientific analysis and the latest translational insights for research and assay optimization.
-
Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X
2026-08-05
The Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O) addresses the critical challenge of preserving protein integrity and phosphorylation states during extraction from diverse biological samples. Its EDTA-free formulation is ideal where metal chelation could compromise downstream applications. This reagent should not be used where EDTA-mediated inhibition or metal chelation is required.
-
Sodium Orthovanadate in Phosphorylation State Preservation W
2026-08-05
Sodium Orthovanadate (Na3VO4) sets a gold standard for preserving tyrosine phosphorylation states and enabling reproducible kinase signaling assays. Its reversible, high-specificity inhibition of phosphatases makes it indispensable in advanced metabolic and insulin signaling studies.
-
PP 2 (AG 1879): Beyond Src Inhibition—Insights for Vascular
2026-08-04
Explore PP 2 (AG 1879) as a selective Src kinase inhibitor and its nuanced applications in vascular and cancer research. This article uniquely bridges mechanistic insights from developmental vascular physiology with methodological guidance for advanced studies.
-
PAD4-IN-2 TFA: Tumor-Selective PAD4 Inhibition for Cancer Re
2026-08-04
PAD4-IN-2 TFA sets a new standard for targeted PAD4 inhibition, leveraging meta-phenylboronic acid modification for unprecedented tumor selectivity. This guide translates recent mechanistic insights and in vivo validation into actionable workflows, troubleshooting strategies, and advanced applications for researchers dissecting NET formation and tumor immune modulation.
-
PBS (Phosphate-Buffered Saline): Technical Use & Protocol Gu
2026-08-03
PBS (Phosphate-Buffered Saline, SKU K2818) provides a sterile, isotonic buffer that maintains physiological pH and osmolarity for in vitro laboratory workflows. It is suitable for procedures such as cell washing, reagent dilution, and protein assays, but should not be used for diagnostic or clinical applications. Researchers benefit from its ready-to-use format and defined storage parameters.
-
Phenylmethanesulfonyl Fluoride (PMSF): Optimizing Protease I
2026-08-03
Phenylmethanesulfonyl fluoride (PMSF) delivers robust, irreversible serine protease inhibition, safeguarding protein integrity for Western blotting, apoptosis assays, and cell signaling research. By mastering PMSF’s protocol nuances and troubleshooting, researchers can overcome proteolytic degradation challenges and achieve reproducible results across molecular workflows.
-
Phosphatase Inhibitor Cocktail 1: Precision in Phosphorylati
2026-08-02
Phosphatase Inhibitor Cocktail 1 (100X in DMSO) empowers researchers to preserve protein phosphorylation states with high fidelity, ensuring robust data for phosphoproteomic workflows and signaling studies. By integrating APExBIO’s advanced inhibitor formulation, laboratories can navigate the complexities of kinase research and Western blotting with greater confidence and reproducibility.